TransThera Sciences (Nanjing). Inc. (2617.HK) Stock Competitors & Peer Comparison
See (2617.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2617.HK | HK$9.10 | -3.50% | 3.6B | -10.34 | -HK$0.88 | N/A |
| 4332.HK | HK$1,850.00 | +0.00% | 998.5B | 16.70 | HK$110.75 | N/A |
| 6160.HK | HK$165.90 | -0.66% | 223.8B | 75.00 | HK$2.21 | N/A |
| 2269.HK | HK$33.04 | -0.18% | 136.9B | 25.85 | HK$1.28 | N/A |
| 1801.HK | HK$75.15 | -1.25% | 130.4B | 138.19 | HK$0.54 | N/A |
| 6990.HK | HK$418.00 | +1.31% | 97.5B | -207.23 | -HK$2.02 | N/A |
| 9926.HK | HK$83.30 | -2.52% | 76.6B | -62.10 | -HK$1.34 | N/A |
| 3347.HK | HK$33.98 | +3.35% | 41.2B | 34.78 | HK$0.98 | +0.43% |
| 6821.HK | HK$111.30 | +2.58% | 40.2B | 36.49 | HK$3.05 | +1.34% |
| 1530.HK | HK$15.91 | -0.93% | 39.8B | 4.14 | HK$3.84 | +1.57% |
Stock Comparison
2617.HK vs 4332.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 4332.HK trades at HK$1,850.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 4332.HK's P/E ratio is 16.70. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 4332.HK's competition here
2617.HK vs 6160.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6160.HK has a market cap of 223.8B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6160.HK trades at HK$165.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6160.HK's P/E ratio is 75.00. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 2617.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6160.HK's competition here
2617.HK vs 2269.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2269.HK has a market cap of 136.9B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2269.HK trades at HK$33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2269.HK's P/E ratio is 25.85. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2269.HK's ROE of +0.11%. Regarding short-term risk, 2617.HK is more volatile compared to 2269.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2269.HK's competition here
2617.HK vs 1801.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1801.HK has a market cap of 130.4B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1801.HK trades at HK$75.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1801.HK's P/E ratio is 138.19. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1801.HK's ROE of +0.05%. Regarding short-term risk, 2617.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1801.HK's competition here
2617.HK vs 6990.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6990.HK has a market cap of 97.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6990.HK trades at HK$418.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6990.HK's P/E ratio is -207.23. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6990.HK's ROE of -0.09%. Regarding short-term risk, 2617.HK is more volatile compared to 6990.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6990.HK's competition here
2617.HK vs 9926.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9926.HK has a market cap of 76.6B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9926.HK trades at HK$83.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9926.HK's P/E ratio is -62.10. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9926.HK's ROE of -0.14%. Regarding short-term risk, 2617.HK is more volatile compared to 9926.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 9926.HK's competition here
2617.HK vs 3347.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 3347.HK has a market cap of 41.2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 3347.HK trades at HK$33.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 3347.HK's P/E ratio is 34.78. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 3347.HK's ROE of +0.04%. Regarding short-term risk, 2617.HK is more volatile compared to 3347.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 3347.HK's competition here
2617.HK vs 6821.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6821.HK has a market cap of 40.2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6821.HK trades at HK$111.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6821.HK's P/E ratio is 36.49. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6821.HK's ROE of +0.06%. Regarding short-term risk, 2617.HK is less volatile compared to 6821.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 6821.HK's competition here
2617.HK vs 1530.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1530.HK has a market cap of 39.8B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1530.HK trades at HK$15.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1530.HK's P/E ratio is 4.14. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1530.HK's ROE of +0.39%. Regarding short-term risk, 2617.HK is more volatile compared to 1530.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1530.HK's competition here
2617.HK vs 2696.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2696.HK has a market cap of 30.2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2696.HK trades at HK$55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2696.HK's P/E ratio is 22.37. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2696.HK's ROE of +0.24%. Regarding short-term risk, 2617.HK is less volatile compared to 2696.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2696.HK's competition here
2617.HK vs 1548.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1548.HK has a market cap of 25.8B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1548.HK trades at HK$11.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1548.HK's P/E ratio is -36.14. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1548.HK's ROE of -0.13%. Regarding short-term risk, 2617.HK is more volatile compared to 1548.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1548.HK's competition here
2617.HK vs 2096.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2096.HK has a market cap of 23.8B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2096.HK trades at HK$9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2096.HK's P/E ratio is 15.65. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2096.HK's ROE of +0.16%. Regarding short-term risk, 2617.HK is more volatile compared to 2096.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2096.HK's competition here
2617.HK vs 1877.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1877.HK has a market cap of 21.6B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1877.HK trades at HK$15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1877.HK's P/E ratio is -22.67. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1877.HK's ROE of -0.11%. Regarding short-term risk, 2617.HK is more volatile compared to 1877.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1877.HK's competition here
2617.HK vs 2162.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2162.HK has a market cap of 18.9B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2162.HK trades at HK$64.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2162.HK's P/E ratio is -30.32. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2162.HK's ROE of -0.17%. Regarding short-term risk, 2617.HK is more volatile compared to 2162.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2162.HK's competition here
2617.HK vs 2315.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2315.HK has a market cap of 16.4B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2315.HK trades at HK$40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2315.HK's P/E ratio is 113.22. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2315.HK's ROE of +0.11%. Regarding short-term risk, 2617.HK is more volatile compared to 2315.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2315.HK's competition here
2617.HK vs 9969.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9969.HK has a market cap of 16.2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9969.HK trades at HK$10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9969.HK's P/E ratio is 24.22. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9969.HK's ROE of +0.10%. Regarding short-term risk, 2617.HK is more volatile compared to 9969.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 9969.HK's competition here
2617.HK vs 9688.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9688.HK has a market cap of 15.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9688.HK trades at HK$13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9688.HK's P/E ratio is -10.98. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9688.HK's ROE of -0.24%. Regarding short-term risk, 2617.HK is more volatile compared to 9688.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 9688.HK's competition here
2617.HK vs 7666.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 7666.HK has a market cap of 15.4B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 7666.HK trades at HK$13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 7666.HK's P/E ratio is -33.46. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 7666.HK's ROE of +2.70%. Regarding short-term risk, 2617.HK is more volatile compared to 7666.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 7666.HK's competition here
2617.HK vs 9606.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9606.HK has a market cap of 14.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9606.HK trades at HK$162.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9606.HK's P/E ratio is -24.17. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9606.HK's ROE of -1.64%. Regarding short-term risk, 2617.HK is more volatile compared to 9606.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 9606.HK's competition here
2617.HK vs 6872.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6872.HK has a market cap of 12.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6872.HK trades at HK$242.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6872.HK's P/E ratio is -70.47. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6872.HK's ROE of -0.58%. Regarding short-term risk, 2617.HK is less volatile compared to 6872.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 6872.HK's competition here
2617.HK vs 2493.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2493.HK has a market cap of 12.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2493.HK trades at HK$22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2493.HK's P/E ratio is -8.53. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2493.HK's ROE of -1.81%. Regarding short-term risk, 2617.HK is less volatile compared to 2493.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2493.HK's competition here
2617.HK vs 6855.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6855.HK has a market cap of 11.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6855.HK trades at HK$30.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6855.HK's P/E ratio is -9.71. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6855.HK's ROE of -1.24%. Regarding short-term risk, 2617.HK is more volatile compared to 6855.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6855.HK's competition here
2617.HK vs 1779.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1779.HK has a market cap of 10.9B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1779.HK trades at HK$150.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1779.HK's P/E ratio is -56.60. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1779.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 1779.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1779.HK's competition here
2617.HK vs 2627.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2627.HK has a market cap of 10.6B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2627.HK trades at HK$29.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2627.HK's P/E ratio is -44.42. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2627.HK's ROE of -2.64%. Regarding short-term risk, 2617.HK is more volatile compared to 2627.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2627.HK's competition here
2617.HK vs 1672.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1672.HK has a market cap of 10.2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1672.HK trades at HK$9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1672.HK's P/E ratio is -23.62. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1672.HK's ROE of -0.19%. Regarding short-term risk, 2617.HK is more volatile compared to 1672.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1672.HK's competition here
2617.HK vs 9887.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9887.HK has a market cap of 9.9B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9887.HK trades at HK$49.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9887.HK's P/E ratio is -381.38. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9887.HK's ROE of -0.10%. Regarding short-term risk, 2617.HK is more volatile compared to 9887.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 9887.HK's competition here
2617.HK vs 2142.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2142.HK has a market cap of 8.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2142.HK trades at HK$10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2142.HK's P/E ratio is 171.00. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2142.HK's ROE of +0.17%. Regarding short-term risk, 2617.HK is more volatile compared to 2142.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2142.HK's competition here
2617.HK vs 2595.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2595.HK has a market cap of 8.2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2595.HK trades at HK$24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2595.HK's P/E ratio is -3.46. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2595.HK's ROE of N/A. Regarding short-term risk, 2617.HK is less volatile compared to 2595.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2595.HK's competition here
2617.HK vs 1952.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1952.HK has a market cap of 8.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1952.HK trades at HK$23.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1952.HK's P/E ratio is -14.15. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1952.HK's ROE of -0.07%. Regarding short-term risk, 2617.HK is more volatile compared to 1952.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1952.HK's competition here
2617.HK vs 6938.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6938.HK has a market cap of 7.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6938.HK trades at HK$44.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6938.HK's P/E ratio is -22.60. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6938.HK's ROE of N/A. Regarding short-term risk, 2617.HK is less volatile compared to 6938.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 6938.HK's competition here
2617.HK vs 2171.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2171.HK has a market cap of 7.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2171.HK trades at HK$13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2171.HK's P/E ratio is -66.44. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2171.HK's ROE of -0.11%. Regarding short-term risk, 2617.HK is less volatile compared to 2171.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2171.HK's competition here
2617.HK vs 6185.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6185.HK has a market cap of 7.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6185.HK trades at HK$20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6185.HK's P/E ratio is -2828.61. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6185.HK's ROE of -0.00%. Regarding short-term risk, 2617.HK is more volatile compared to 6185.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6185.HK's competition here
2617.HK vs 2616.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2616.HK has a market cap of 7.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2616.HK trades at HK$4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2616.HK's P/E ratio is -17.93. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2616.HK's ROE of -0.65%. Regarding short-term risk, 2617.HK is more volatile compared to 2616.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2616.HK's competition here
2617.HK vs 2256.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2256.HK has a market cap of 6.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2256.HK trades at HK$9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2256.HK's P/E ratio is -41.13. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2256.HK's ROE of +0.11%. Regarding short-term risk, 2617.HK is more volatile compared to 2256.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2256.HK's competition here
2617.HK vs 9966.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9966.HK has a market cap of 6.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9966.HK trades at HK$6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9966.HK's P/E ratio is 27.24. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9966.HK's ROE of -0.06%. Regarding short-term risk, 2617.HK is more volatile compared to 9966.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 9966.HK's competition here
2617.HK vs 2157.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2157.HK has a market cap of 6.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2157.HK trades at HK$3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2157.HK's P/E ratio is -32.71. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2157.HK's ROE of +0.24%. Regarding short-term risk, 2617.HK is more volatile compared to 2157.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2157.HK's competition here
2617.HK vs 6826.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6826.HK has a market cap of 6.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6826.HK trades at HK$15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6826.HK's P/E ratio is 20.64. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6826.HK's ROE of +0.04%. Regarding short-term risk, 2617.HK is more volatile compared to 6826.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6826.HK's competition here
2617.HK vs 2629.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2629.HK has a market cap of 3.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2629.HK trades at HK$12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2629.HK's P/E ratio is -5.75. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2629.HK's ROE of N/A. Regarding short-term risk, 2617.HK is less volatile compared to 2629.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2629.HK's competition here
2617.HK vs 1477.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1477.HK has a market cap of 3.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1477.HK trades at HK$4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1477.HK's P/E ratio is -18.85. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1477.HK's ROE of -0.04%. Regarding short-term risk, 2617.HK is more volatile compared to 1477.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1477.HK's competition here
2617.HK vs 1167.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1167.HK has a market cap of 3.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1167.HK trades at HK$4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1167.HK's P/E ratio is -41.03. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1167.HK's ROE of -0.18%. Regarding short-term risk, 2617.HK is less volatile compared to 1167.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 1167.HK's competition here
2617.HK vs 3880.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 3880.HK has a market cap of 3.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 3880.HK trades at HK$22.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 3880.HK's P/E ratio is 24.63. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 3880.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 3880.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 3880.HK's competition here
2617.HK vs 2591.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2591.HK has a market cap of 3.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2591.HK trades at HK$6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2591.HK's P/E ratio is -7.42. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2591.HK's ROE of -0.38%. Regarding short-term risk, 2617.HK is more volatile compared to 2591.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2591.HK's competition here
2617.HK vs 2509.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2509.HK has a market cap of 3.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2509.HK trades at HK$13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2509.HK's P/E ratio is 8.35. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2509.HK's ROE of -0.32%. Regarding short-term risk, 2617.HK is more volatile compared to 2509.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2509.HK's competition here
2617.HK vs 6955.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6955.HK has a market cap of 2.8B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6955.HK trades at HK$4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6955.HK's P/E ratio is 453.00. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6955.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 6955.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6955.HK's competition here
2617.HK vs 2105.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2105.HK has a market cap of 2.8B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2105.HK trades at HK$6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2105.HK's P/E ratio is -9.15. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2105.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 2105.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2105.HK's competition here
2617.HK vs 2480.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2480.HK has a market cap of 2.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2480.HK trades at HK$12.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2480.HK's P/E ratio is -14.72. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2480.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 2480.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2480.HK's competition here
2617.HK vs 2659.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2659.HK has a market cap of 2.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2659.HK trades at HK$16.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2659.HK's P/E ratio is -10.39. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2659.HK's ROE of N/A. Regarding short-term risk, 2617.HK is less volatile compared to 2659.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2659.HK's competition here
2617.HK vs 2179.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2179.HK has a market cap of 2.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2179.HK trades at HK$4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2179.HK's P/E ratio is -3.17. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2179.HK's ROE of -1.37%. Regarding short-term risk, 2617.HK is more volatile compared to 2179.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2179.HK's competition here
2617.HK vs 1873.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1873.HK has a market cap of 2.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1873.HK trades at HK$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1873.HK's P/E ratio is 17.64. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1873.HK's ROE of +0.06%. Regarding short-term risk, 2617.HK is more volatile compared to 1873.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1873.HK's competition here
2617.HK vs 1875.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1875.HK has a market cap of 2.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1875.HK trades at HK$3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1875.HK's P/E ratio is 295.75. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1875.HK's ROE of -0.15%. Regarding short-term risk, 2617.HK is less volatile compared to 1875.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 1875.HK's competition here
2617.HK vs 6681.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6681.HK has a market cap of 2.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6681.HK trades at HK$1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6681.HK's P/E ratio is -13.89. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6681.HK's ROE of +7.95%. Regarding short-term risk, 2617.HK is less volatile compared to 6681.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 6681.HK's competition here
2617.HK vs 2197.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2197.HK has a market cap of 2.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2197.HK trades at HK$1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2197.HK's P/E ratio is -2.08. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2197.HK's ROE of +0.11%. Regarding short-term risk, 2617.HK is more volatile compared to 2197.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2197.HK's competition here
2617.HK vs 6660.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6660.HK has a market cap of 2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6660.HK trades at HK$1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6660.HK's P/E ratio is -2.58. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6660.HK's ROE of -0.22%. Regarding short-term risk, 2617.HK is more volatile compared to 6660.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6660.HK's competition here
2617.HK vs 6996.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6996.HK has a market cap of 2B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6996.HK trades at HK$3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6996.HK's P/E ratio is -7.78. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6996.HK's ROE of -0.34%. Regarding short-term risk, 2617.HK is less volatile compared to 6996.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 6996.HK's competition here
2617.HK vs 1521.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1521.HK has a market cap of 1.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1521.HK trades at HK$0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1521.HK's P/E ratio is 52.99. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1521.HK's ROE of +0.02%. Regarding short-term risk, 2617.HK is less volatile compared to 1521.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 1521.HK's competition here
2617.HK vs 2181.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2181.HK has a market cap of 1.7B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2181.HK trades at HK$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2181.HK's P/E ratio is -12.63. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2181.HK's ROE of +0.44%. Regarding short-term risk, 2617.HK is more volatile compared to 2181.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2181.HK's competition here
2617.HK vs 1541.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1541.HK has a market cap of 1.5B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1541.HK trades at HK$3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1541.HK's P/E ratio is -4.40. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1541.HK's ROE of -0.33%. Regarding short-term risk, 2617.HK is more volatile compared to 1541.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 1541.HK's competition here
2617.HK vs 2565.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2565.HK has a market cap of 1.4B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2565.HK trades at HK$4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2565.HK's P/E ratio is -7.75. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2565.HK's ROE of N/A. Regarding short-term risk, 2617.HK is less volatile compared to 2565.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2565.HK's competition here
2617.HK vs 2566.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2566.HK has a market cap of 1.4B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2566.HK trades at HK$5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2566.HK's P/E ratio is 8.91. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2566.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 2566.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2566.HK's competition here
2617.HK vs 2511.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2511.HK has a market cap of 1.4B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2511.HK trades at HK$2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2511.HK's P/E ratio is -3.88. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2511.HK's ROE of -0.39%. Regarding short-term risk, 2617.HK is more volatile compared to 2511.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2511.HK's competition here
2617.HK vs 6622.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6622.HK has a market cap of 1.3B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6622.HK trades at HK$2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6622.HK's P/E ratio is -4.41. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6622.HK's ROE of -0.13%. Regarding short-term risk, 2617.HK is more volatile compared to 6622.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6622.HK's competition here
2617.HK vs 3681.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 3681.HK has a market cap of 1.1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 3681.HK trades at HK$1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 3681.HK's P/E ratio is -5.43. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 3681.HK's ROE of -0.28%. Regarding short-term risk, 2617.HK is more volatile compared to 3681.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 3681.HK's competition here
2617.HK vs 2898.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2898.HK has a market cap of 1B. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2898.HK trades at HK$6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2898.HK's P/E ratio is -10.49. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2898.HK's ROE of -0.17%. Regarding short-term risk, 2617.HK is more volatile compared to 2898.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2898.HK's competition here
2617.HK vs 2487.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2487.HK has a market cap of 981.1M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2487.HK trades at HK$2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2487.HK's P/E ratio is -1.69. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2487.HK's ROE of -0.41%. Regarding short-term risk, 2617.HK is more volatile compared to 2487.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2487.HK's competition here
2617.HK vs 6998.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6998.HK has a market cap of 876.1M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6998.HK trades at HK$1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6998.HK's P/E ratio is -3.13. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6998.HK's ROE of +0.18%. Regarding short-term risk, 2617.HK is more volatile compared to 6998.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6998.HK's competition here
2617.HK vs 9939.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 9939.HK has a market cap of 867.5M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 9939.HK trades at HK$1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 9939.HK's P/E ratio is -4.56. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 9939.HK's ROE of -0.99%. Regarding short-term risk, 2617.HK is less volatile compared to 9939.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 9939.HK's competition here
2617.HK vs 2592.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2592.HK has a market cap of 866.2M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2592.HK trades at HK$1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2592.HK's P/E ratio is -1.29. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2592.HK's ROE of N/A. Regarding short-term risk, 2617.HK is more volatile compared to 2592.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2592.HK's competition here
2617.HK vs 1228.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1228.HK has a market cap of 849.7M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1228.HK trades at HK$2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1228.HK's P/E ratio is -3.04. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1228.HK's ROE of -0.04%. Regarding short-term risk, 2617.HK is less volatile compared to 1228.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 1228.HK's competition here
2617.HK vs 2496.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2496.HK has a market cap of 762.7M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2496.HK trades at HK$3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2496.HK's P/E ratio is -7.45. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2496.HK's ROE of +4.85%. Regarding short-term risk, 2617.HK is more volatile compared to 2496.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2496.HK's competition here
2617.HK vs 2137.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2137.HK has a market cap of 685.1M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2137.HK trades at HK$0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2137.HK's P/E ratio is -3.02. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2137.HK's ROE of -0.09%. Regarding short-term risk, 2617.HK is more volatile compared to 2137.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2137.HK's competition here
2617.HK vs 2126.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2126.HK has a market cap of 624.7M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2126.HK trades at HK$1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2126.HK's P/E ratio is -0.98. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2126.HK's ROE of -0.75%. Regarding short-term risk, 2617.HK is more volatile compared to 2126.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2126.HK's competition here
2617.HK vs 1244.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 1244.HK has a market cap of 624.6M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 1244.HK trades at HK$2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 1244.HK's P/E ratio is -3.06. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 1244.HK's ROE of -0.27%. Regarding short-term risk, 2617.HK is less volatile compared to 1244.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 1244.HK's competition here
2617.HK vs 0690.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 0690.HK has a market cap of 519.5M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 0690.HK trades at HK$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 0690.HK's P/E ratio is 6.47. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 0690.HK's ROE of +0.23%. Regarding short-term risk, 2617.HK is less volatile compared to 0690.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 0690.HK's competition here
2617.HK vs 2257.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2257.HK has a market cap of 500.9M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2257.HK trades at HK$4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2257.HK's P/E ratio is -3.47. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2257.HK's ROE of +1.92%. Regarding short-term risk, 2617.HK is more volatile compared to 2257.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 2257.HK's competition here
2617.HK vs 6628.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6628.HK has a market cap of 473.1M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6628.HK trades at HK$1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6628.HK's P/E ratio is -1.24. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6628.HK's ROE of -0.28%. Regarding short-term risk, 2617.HK is less volatile compared to 6628.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 6628.HK's competition here
2617.HK vs 2185.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2185.HK has a market cap of 440.8M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2185.HK trades at HK$1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2185.HK's P/E ratio is -3.01. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2185.HK's ROE of -0.15%. Regarding short-term risk, 2617.HK is less volatile compared to 2185.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2185.HK's competition here
2617.HK vs 2396.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 2396.HK has a market cap of 347M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 2396.HK trades at HK$4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 2396.HK's P/E ratio is -1.73. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 2396.HK's ROE of N/A. Regarding short-term risk, 2617.HK is less volatile compared to 2396.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2617.HK.Check 2396.HK's competition here
2617.HK vs 6978.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 6978.HK has a market cap of 272.1M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 6978.HK trades at HK$0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 6978.HK's P/E ratio is -1.37. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 6978.HK's ROE of +2.93%. Regarding short-term risk, 2617.HK is more volatile compared to 6978.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 6978.HK's competition here
2617.HK vs 8158.HK Comparison June 2026
2617.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2617.HK stands at 3.6B. In comparison, 8158.HK has a market cap of 97.4M. Regarding current trading prices, 2617.HK is priced at HK$9.10, while 8158.HK trades at HK$0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2617.HK currently has a P/E ratio of -10.34, whereas 8158.HK's P/E ratio is -0.88. In terms of profitability, 2617.HK's ROE is -0.74%, compared to 8158.HK's ROE of +0.80%. Regarding short-term risk, 2617.HK is more volatile compared to 8158.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2617.HK.Check 8158.HK's competition here